Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Inks Distribution Deal for France

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.

The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.

The portfolio includes a research assay for KRAS and BRAF mutations, an IVD assay that uses RNA from blood or bone marrow to help diagnose certain leukemias, and an assay for simultaneous detection of common NPM1 mutations.

In addition, BMD will support Asuragen's efforts to establish clinical validation sites for the Signature KRAS/BRAF assay in France, Asuragen said.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.